KarXT
Oct 14, 2025
5 Upcoming Schizophrenia Drugs Competitors for Newly Approved BMS’ KarXT (COBENFY)
After years of little progress in the field of schizophrenia drug treatment, Bristol Myers Squibb’s USD 14 billion acquisition of Karuna Therapeutics has paid off with the approval of a groundbreaking new drug. BMS’s novel medication, KarXT—now named COBENFY—received FDA approval on 26 September 2024 for the treatm...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
